Evaluating Safety and Effectiveness of Anti-HER2 Therapy with Chemotherapy in Nigerian Women Aged 18-70 With HER2-Positive Breast Cancer Before and After Surgery

What this Trial Is About

This research aims to evaluate cancer treatment based on HER2 status in Nigerian women with HER2-positive breast cancer. The study focuses on assessing the safety and effectiveness of anti-HER2 therapy given before and after surgery. It specifically looks at how well the treatment works and its safety when combined with chemotherapy. Participants will receive a combination of trastuzumab and pertuzumab PHESGO along with chemotherapy. Initially, all participants get docetaxel injections for 4-6 cycles while receiving trastuzumab and pertuzumab as subcutaneous injections for 52 weeks. Depending on how their cancer responds after this phase, some will undergo surgery and continue receiving pertuzumab and trastuzumab for 36 weeks, possibly with hormone therapy such as tamoxifen, letrozole, or goserelin. Others with less favorable responses will receive trastuzumab emtansine intravenously plus standard chemotherapy. During the study, participants will have regular assessments including ultrasounds to monitor tumor response, laboratory tests, and echocardiograms to check heart function. Researchers will track outcomes like pathological complete response, adverse events, quality of life, and survival over 10 years. The study involves continuous monitoring and follow-up to evaluate treatment effects and safety throughout this period.

Assessing the Efficacy and Safety of Anti-HER2 Therapy in Nigerian Women With HER2+ Breast Cancer Before and After Surgery